Tuesday 13 November 2018 | ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares
Having filed patents and announced the start of the technology programme last year, Cambridge Cognition (COG) has now announced its “first voice-based cognitive assessments are available for use in its core pharmaceutical and biotechnology clinical trial channels”…
The theme of Monday's UK Investor City Show evening was disruptive technologies. That is certainly something Cambridge Cognition (COG) is working on. Nigel Wray is a big shareholders and has increased his stake of late. Watch the video to see why.
This is from HotStockRockets at the end of last month; tipped at a 145p offer price, and now circa 170p - to catch such articles first click HERE... To see Britain’s Buffett, Nigel Wray, at the top of the shareholders list is always an encouraging sign and with Cambridge Cognition (COG) this is added to by recent developments…
Having listed on AIM in 2013 at 70p per share to “accelerate the rollout of CANTABmobile, our point of care cognitive test for GPs and dementia specialists”, shares in Cambridge Cognition (COG) currently trade approaching 20% lower today at around 55p on the back of a “Trading Update” including the company “not quite meeting earnings expectations for 2015”. This though follows a November update on expected contracts to “ensure that, despite increasing investment in both healthcare technology development and commercial infrastructure in the USA, the outturn for this year should be similar to 2014 and provide a strong contracted revenue base for the next fiscal year”. Hmmm…
It has to be said, that if nothing else Cambridge Cognition Holdings has an intellectual / boffin type of ring to it. On a more “scientific” charting view we can see what is clearly a relatively lightly traded stock over the past year, but one that looks to be in recovery mode.
Search ShareProphets |
Recent Comments |